How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,999 results for

Conjunctivitis Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Conjunctivitis Resources

Conjunctivitis Resources Conjunctivitis Resources Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Conjunctivitis Resources (...) Conjunctivitis Resources Aka: Conjunctivitis Resources From Related Chapters II. Patient Education Handouts in Childhood (Dr. Moshe Ipp) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Conjunctivitis Resources." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Conjunctival Disorders About FPnotebook.com is a rapid access, point-of-care medical

2018 FP Notebook

2. Resource utilization: why do we overdo it?

instructions. Risk Tolerance In conjunction with diagnostic uncertainty, risk tolerance has been cited as another reason for increased resource utilization. Studies have demonstrated that risk averse physicians order statistically more tests than their colleagues, with no differences in adverse outcomes 7 . In particular, three studies examining this, correlated diagnostic testing in the ED with physician risk tolerance (as determined by utilizing three validated risk tolerance personality scores (...) Resource utilization: why do we overdo it? Resource utilization: why do we overdo it? - CanadiEM Resource utilization: why do we overdo it? In , by Shahbaz Syed November 2, 2016 There is a plethora of evidence that suggests, as physicians we over-diagnose, over-treat and over-investigate illness, often with little benefit to patients. The idea of rationale resource utilization is beginning to gain momentum, with campaigns such as , advocating for physicians to use the best evidence available

2016 CandiEM

3. Effect of Mobilization in Conjunction With Exercise in Participants With a History of Chronic Ankle Instability

: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment Official Title: Effect of a Six-week Rehabilitation Program in Conjunction With Thrust Mobilization on Lower Extremity Function in Subjects Reporting Chronic Ankle Instability Actual Study Start Date : February 14, 2018 Estimated Primary Completion Date : January 2019 Estimated Study Completion Date : June 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm (...) Effect of Mobilization in Conjunction With Exercise in Participants With a History of Chronic Ankle Instability Effect of Mobilization in Conjunction With Exercise in Participants With a History of Chronic Ankle Instability - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

4. A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Title: An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC) Actual Study Start Date : October 2, 2018 Estimated Primary Completion Date : March 2019 Estimated Study Completion Date : March 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Reproxalap Ophthalmic Solution (...) A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

5. Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03749317 Recruitment Status : Not yet recruiting First Posted : November 21

2018 Clinical Trials

6. Conjunctivitis in the Newborn

Perspective: Prospective Official Title: Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT). Actual Study Start Date : September 9, 2015 Actual Primary Completion Date : May 12, 2016 Actual Study Completion Date : July 24, 2016 Resource links provided by the National Library of Medicine related topics: resources: Groups and Cohorts Go to Group/Cohort Intervention/treatment Prophylaxis group Newborns treated with rifamycin eye drops (...) Conjunctivitis in the Newborn Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2018 Clinical Trials

7. Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

Purpose: Treatment Official Title: Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment Actual Study Start Date : July 31, 2018 Estimated Primary Completion Date : July 29, 2019 Estimated Study Completion Date : December 20, 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm (...) Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2018 Clinical Trials

8. A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial With Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis Actual Study Start Date : September 8, 2018 Estimated Primary Completion Date : February 2019 Estimated Study Completion Date : February 2019 Resource links provided by the National Library (...) A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

9. Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.

in the bottles and the use of identical labels that contain the assignment number. Primary Purpose: Treatment Official Title: Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%. Actual Study Start Date : October 1, 2018 Estimated Primary Completion Date : January 31, 2020 Estimated Study Completion Date : April 2020 Resource links provided by the National Library (...) Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2018 Clinical Trials

10. Seasonal and Temporal Trends in Childhood Conjunctivitis in Burkina Faso. (PubMed)

. A total of 783,314 cases were reported over the 4-year period. Conjunctivitis followed a seasonal pattern throughout the country, with a peak in April. A nationwide conjunctivitis outbreak with a peak in September 2016 was noted (P < 0.001), with an excess number of cases first detected in June 2016. Nationwide passive surveillance was able to detect an epidemic 3 months before its peak, which may aide in allocation of resources for containment and mitigation of transmission in future outbreaks. (...) Seasonal and Temporal Trends in Childhood Conjunctivitis in Burkina Faso. Acute conjunctivitis follows a seasonal pattern. Although its clinical course is typically self-limited, conjunctivitis epidemics incur a substantial economic burden because of missed school and work days. This study investigated seasonal and temporal trends of childhood conjunctivitis in the entire country of Burkina Faso from 2013 to 2016, using routine monthly surveillance from 2,444 government health facilities

2018 American Journal of Tropical Medicine & Hygiene

11. VA mobile apps for PTSD and related problems: public health resources for veterans and those who care for them (PubMed)

VA mobile apps for PTSD and related problems: public health resources for veterans and those who care for them Many public health agencies, including the U.S. Department of Veterans Affairs (VA), have identified the use of mobile technologies as an essential part of a larger strategy to address major public health challenges. The VA's National Center for PTSD (NCPTSD), in collaboration with VA's Office of Mental Health and Suicide Prevention and the Defense Health Agency inside the U.S (...) . Department of Defense (DoD), has been involved in the development, evaluation, and testing of 15 mobile apps designed specifically to address the needs and concerns of veterans and others experiencing symptoms of posttraumatic stress disorder (PTSD). These applications include seven treatment-companion apps (designed to be used with a provider, in conjunction with an evidence-based therapy) and eight self-management apps (designed to be used independently or as an adjunct or extender of traditional care

Full Text available with Trip Pro

2018 mHealth

12. Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness

with cromoglycate the number of repeat GP visits was expected to be 7.9 to 10.5 million over a 4 month period. . “Use of olopatadine instead of branded or generic cromoglycate affords an economic benefit to NHS. Hence, within the limitations of the model, olopatadine is the preferred first-line treatment for use in SAC sufferers, since it is expected to lead to lower GP visits, thereby releasing healthcare resources for alternative use.” (p. 1777) Olopatadine for the Treatment of Allergic Conjunctivitis 29 (...) Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Comparing TR Band to Statseal in Conjunction With TR Band

Comparing TR Band to Statseal in Conjunction With TR Band Comparing TR Band to Statseal in Conjunction With TR Band - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparing TR Band to Statseal (...) in Conjunction With TR Band The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03028025 Recruitment Status : Completed First Posted : January 23, 2017 Results First Posted : March 12, 2018 Last Update Posted : March 12, 2018 Sponsor: VA Long Beach Healthcare System Information provided by (Responsible Party

2017 Clinical Trials

14. Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

15. A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

Allergic Conjunctivitis Actual Study Start Date : February 26, 2018 Estimated Primary Completion Date : March 2019 Estimated Study Completion Date : August 2019 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Intervention Details: Drug: AK002 AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (...) A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2017 Clinical Trials

16. Epidemiology of Conjunctivitis in the Emergency Department

Completion Date : September 3, 2017 Actual Study Completion Date : November 1, 2017 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Evaluation of the main etiologies of acute infectious conjunctivitis in the Emergency Department of a Reference Hospital in Goiânia. [ Time Frame: 126 days ] Through clinical diagnosis in the Emergency Department Eligibility Criteria Go to Information from the National (...) Epidemiology of Conjunctivitis in the Emergency Department Epidemiology of Conjunctivitis in the Emergency Department - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Epidemiology of Conjunctivitis

2017 Clinical Trials

17. A Study Evaluating the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm

of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm Actual Study Start Date : October 15, 2018 Estimated Primary Completion Date : September 30, 2021 Estimated Study Completion Date : December 31, 2025 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment Group PulseRider® Aneurysm Neck (...) A Study Evaluating the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm A Study Evaluating the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm - Full Text View - ClinicalTrials.gov Hide glossary

2017 Clinical Trials

18. Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

19. Study to Evaluate the Safety and Initial Effectiveness of the Sinuswayâ„¢ for Endoscopy of Sinuses in Conjunction With BSD

) Primary Purpose: Diagnostic Official Title: Safety and Effectiveness Evaluation of the Sinusway™ Device for Endoscopy of the Nasal Cavity and Paranasal Sinuses in Conjunction With Sinus Balloon Dilation Actual Study Start Date : April 25, 2017 Estimated Primary Completion Date : April 2018 Estimated Study Completion Date : July 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 3NT flexible endoscope (...) Study to Evaluate the Safety and Initial Effectiveness of the Sinuswayâ„¢ for Endoscopy of Sinuses in Conjunction With BSD Study to Evaluate the Safety and Initial Effectiveness of the Sinusway™ for Endoscopy of Sinuses in Conjunction With BSD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

20. Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tum

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tum Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without (...) Papillary Tumors. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>